These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2013 Archives

Nov 26, 2013
Nov 20, 2013
GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8 MILLION
Nov 1, 2013
Oct 16, 2013
Phase II Trial to Focus on Moderate to Severe UC Patients with Eotaxin-1 Biomarker
Oct 15, 2013
New Members Provide strong financing and operating experience
Oct 3, 2013
Sep 30, 2013
Company to Transfer Swedish Listing to NASDAQ OMX First North Premier
Sep 23, 2013
Sep 4, 2013
Aug 27, 2013
New Three-Year Term Enables Focus on Product Development
Aug 26, 2013
Common Stock Trading on Nasdaq OMX Stockholm Exchange and OTCQX Trading Platform
Aug 20, 2013
Merger with Immune Expected to Close this Week
Aug 1, 2013
Special August 6 Stockholder Meeting to Approve Final Conditions to Merger with Immune Pharmaceuticals
Jun 20, 2013
Positive Vote Required to Enable Merger Closing
Jun 3, 2013
May 22, 2013
UPDATE ON BERTILIMUMAB DEVELOPMENT AND EPICEPT MERGER PROCESS
May 20, 2013
PRELIMINARY PROXY STATEMENT FOR MERGER FILED WITH SEC
Feb 28, 2013
Feb 21, 2013
Bertilimumab Targets Eotaxin-1, a Chemokine Over-Expressed in Ulcerative Colitis Patients
Feb 12, 2013
IMMUNE TO PROVIDE EPICEPT WITH UP TO $0.5 MILLION IN WORKING CAPITAL
Feb 6, 2013
Jan 9, 2013
 

print email rss